Field of Interest: Oncology

Certain refractory prostate cancers respond to olaparib

Daily oral olaparib induced a 33% response rate in refractory, progressing prostate cancer in an international phase II clinical trial. The study was published online Oct. 29 in the New England...

Field of Interest: Oncology
Type: News Item

Urinary biomarkers miss the mark for bladder cancer

When used alone, urinary biomarkers miss a substantial proportion of patients with bladder cancer and are subject to false-positive results in others, and the accuracy is poor for low-stage and...

Field of Interest: Oncology
Type: News Item

Blacks receive inferior care for localized prostate cancer

Black patients with localized prostate cancer who underwent radical prostatectomy received inferior surgical care, compared with whites, as evidenced by fewer lymph node dissections and longer delays...

Field of Interest: Oncology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.